Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment of Atopic Derma...
June 20 2017 - 3:05AM
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care, today announced receipt of two
new regulatory approvals from the Singapore government for its
Microcyn® Technology-based hydrogels.
The first approval is for EZyma™ Hydrogel, which is intended for
the management of itching dryness, redness, burning and pain
associated with atopic dermatitis. The second clearance is
for ScarLess™ Hydrogel to be used as an adjuvant in the wound
healing process as well for managing and reducing new and existing
hypertrophic and keloid scars.
“We have seen these dermatological hydrogels successfully
address both atopic dermatitis and management of scars around the
globe,” said Bruce Thornton, Sonoma Pharmaceuticals vice president
of international sales. “So we are most pleased to be able to
bring these innovative technologies to dermatologists and plastic
surgeons in Singapore and Malaysia, thus enabling these healthcare
professionals to further improve patient outcomes.”
Sonoma’s distribution partner in Singapore, Dyamed Biotech, will
launch both products in September 2017.
Theodore Tan, managing director and co-founder of Dyamed, said,
“For over 12 years our strong and close partnership has continued
to grow with Sonoma Phrmaceuticals and we are very excited to
introduce the next line of Microcyn-based products for dermatology
use in Singapore and Malaysia with EZyma and ScarLess.”
About Atopic DermatitisIn a 2015 study
published in the Annals of Nutrition & Metabolism, atopic
dermatitis is shown to be a chronic inflammatory skin disease
posing a significant burden on health-care resources and patients'
quality of life. A complex disease with a wide spectrum of clinical
presentations and combinations of symptoms, atopic dermatitis
affects up to 20% of children and up to 3% of adults; recent data
show that its prevalence is still increasing, especially in
low-income countries.
Scar Treatment MarketAccording to a P&S
Market Research report, the global scar treatment market accounted
for $15,944 billion in revenue in 2015, and it is expected to grow
at a CAGR of 10.0% during 2016-2022. The topical treatment segment
dominated the global market in 2015 with about 60.9% share. The
global scar treatment market is witnessing high growth rate, due to
growing cases with skin problems leading to scar formation,
availability of technologically advanced products, which have the
capability to fade away the scars and increasing appearance
consciousness among consumers. Also, the increasing expenditure on
personal care is further propelling the growth of the market.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies, the
Company may not meet its future capital needs, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission including its annual report on Form 10-K. The
Company disclaims any obligation to update these forward-looking
statements, except as required by law.
Sonoma Pharmaceuticals® and Microcyn® Technology are trademarks
or registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@Sonomais.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Apr 2024 to May 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From May 2023 to May 2024